[
    [
        {
            "time": "",
            "original_text": "贝达药业（300558.SZ）：拟斥不超8000万美元认购Xcovery新发行F轮优先股 持股比例升至69.53%",
            "features": {
                "keywords": [
                    "贝达药业",
                    "Xcovery",
                    "F轮优先股",
                    "8000万美元",
                    "持股比例",
                    "69.53%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业（300558.SZ）：拟斥不超8000万美元认购Xcovery新发行F轮优先股 持股比例升至69.53%",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业（300558.SZ）拟认购Xcovery新发行F轮优先股 推进恩沙替尼项目",
            "features": {
                "keywords": [
                    "贝达药业",
                    "Xcovery",
                    "F轮优先股",
                    "恩沙替尼"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业（300558.SZ）拟认购Xcovery新发行F轮优先股 推进恩沙替尼项目",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：不超8000万美元认购Xcovery新发行F轮优先股",
            "features": {
                "keywords": [
                    "贝达药业",
                    "Xcovery",
                    "F轮优先股",
                    "8000万美元"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：不超8000万美元认购Xcovery新发行F轮优先股",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "创新药周报：2021年9月第五周",
            "features": {
                "keywords": [
                    "创新药",
                    "周报",
                    "2021年9月第五周"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "创新药周报：2021年9月第五周",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "解密益方生物等创新药授权合作模式 挖掘医药“潜力股” | 新闻稿",
            "features": {
                "keywords": [
                    "益方生物",
                    "创新药",
                    "授权合作",
                    "潜力股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "解密益方生物等创新药授权合作模式 挖掘医药“潜力股” | 新闻稿",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "兴证医药2021年10月投资月报：新冠药物新冠疫苗专题分析",
            "features": {
                "keywords": [
                    "兴证医药",
                    "2021年10月",
                    "投资月报",
                    "新冠药物",
                    "新冠疫苗"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "兴证医药2021年10月投资月报：新冠药物新冠疫苗专题分析",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 1,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        }
    ]
]